Health

EssilorLuxottica completes acquisition of Optegra

EssilorLuxottica completes acquisition of Optegra Paris, France (1 October 2025) – EssilorLuxottica announces that it has successfully completed the acquisition…

3 months ago

The Facial Pain Association (FPA) Highlights Trigeminal Neuralgia and the Facial Pain Community during Facial Pain Awareness Month

SUWANEE, Ga., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Throughout October, the Facial Pain Association (FPA) commemorates Facial Pain Awareness Month…

3 months ago

Cirtec Medical Appoints Steven Chevillotte to its Board of Directors

October 01, 2025 13:01 ET  | Source: Cirtec Medical BROOKLYN PARK, Minn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical,…

3 months ago

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

September 30, 2025 17:25 ET  | Source: YD Bio Limited TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited…

4 months ago

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck…

4 months ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025 16:24 ET  | Source: Pyxis Oncology BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq:…

4 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

September 29, 2025 19:30 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge and London, UK, 30 September 2025 –…

4 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

September 29, 2025 19:15 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences,…

4 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

4 months ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of…

4 months ago